phase readout
saveNCT06384261: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
ACTIVE_NOT_RECRUITINGupdated 1d ago
community read0 votes
Sponsor: OncoVerity, Inc.. Phase: PHASE2. Conditions: Leukemia, Myeloid, Acute
view source ↗
comments(0)
5-min edit window · permanent after that